SUMMARY. Noninjection drug use, although recognized as an emerging risk factor for acquisition of other blood-born pathogens, is still unconfirmed as a route of hepatitis C virus (HCV) transmission. Our goal was to measure HCV exposure and prevalence in noninjection drug users (NIDUs). Fiftyseven NIDUs were screened by extensive questionnaire to exclude prior injection drug use and evaluated for HCV-specific serologic and cellular immune responses. HCVspecific T-cell responses were measured using interferongamma (IFN-c) enzyme-linked immunospot (ELISpot) assay with overlapping HCV peptides covering the entire HCV genome. Fifteen individuals who never used illicit drugs served as negative controls. Eleven people with no history of injecting drug use (19.3%) were HCV seropositive: seven with chronic HCV infection and four with previously resolved infection. Of 51 NIDUs with ELISpot results, HCVspecific cellular immunity was detected in 5 (9.8%). These responses were relatively weak and narrow. We did not find significant associations between HCV-specific immune responses and noninjection drug use practices. Subjects with HCV-specific immunity, however, were significantly more likely to have bought sex in the past 6 months, to have had more casual partners of the opposite sex in the last 6 months, and those partners were more likely to have ever injected drugs compared to subjects without HCV-specific immunity. In summary, we found serologic or cellular HCVspecific immune responses in 27.5% of NIDUs. Our results suggest that sexual behaviour associated with noninjection drug use might be a risk factor for HCV acquisition. Additional studies are needed to precisely determine the practices that lead to HCV exposure among this population.
INTRODUCTION
Hepatitis C virus (HCV) infection is a global health problem with >120 million people affected worldwide and >5 million people in the United States [1] [2] [3] . Although some patients spontaneously resolve HCV infection, the majority develops chronic liver disease that can progress to cirrhosis and/or hepatocellular carcinoma. Currently, injection drug use represents the primary mode of HCV transmission in developed countries with >80% prevalence among older injection drug users (IDUs) and incidence rates ranging from 10% to >20% annually [4] [5] [6] [7] [8] [9] [10] .
Although still controversial, noninjection drug use is recognized as an emerging risk factor for HCV acquisition. HCV prevalence among noninjection drug users (NIDUs) ranges from 2% to 35%, significantly greater than that observed in the general population [11] . Although the mechanism of HCV transmission among NIDUs is incompletely understood, sharing of equipment used for administration of illicit drugs is the most plausible explanation [12] . HCV RNA has been detected in saliva [13, 14] , gingival crevicular fluid [14] , and nasal secretions [15] in HCV-infected people. Additionally, vasoconstricting effects or irritation caused by illicit drugs, specifically cocaine or methamphetamine, might disrupt mucous membranes [16] . Finally, individuals with chronic substance abuse display high rates of dental abnormalities [16] . Therefore, blood or saliva on inhalation equipment together with drug-induced lesions of mucous membranes is a potential mechanism by which noninjection drug use could result in HCV infection.
Spontaneous clearance of HCV infection is recognized in aviremic patients through the detection of HCV-specific serologic responses. However, some people may clear the infection without developing antibodies while, in others, antibodies may develop and wane over time [17, 18] . HCVspecific cellular immunity has been reported in antibodynegative persons who may have had viral exposure, such as healthcare workers [19] , spouses and other family members of HCV-infected individuals [20, 21] , and prison inmates [17] . HCV-specific cellular immune responses have also been detected in 46-72% of seronegative IDUs, suggesting their prior exposure to the virus [22] [23] [24] . These findings suggest that cellular immunity alone may be sufficient for viral eradication. Alternatively, frequent exposure to small viral quantities may lead to the development of cellular immunity without seroconversion or productive HCV infection. Consequently, antibody measurement alone does not identify all individuals previously exposed to HCV.
We evaluated HCV-specific cellular and antibody responses in 57 NIDUs who never injected drugs. Detailed information on subjectsÕ drug use and sexual practices was collected through comprehensive questionnaires. Associations between HCV-specific immune responses and drug administration behaviours were analyzed to determine factors that increase the likelihood of HCV infection.
MATERIALS AND METHODS

SubjectsÕ characteristics
Fifty-seven NIDUs were recruited from the Beth Israel Medical Center (BIMC) drug detoxification program between March 2009 and September 2010. Our subjects are a subset of a larger group of drug users recruited for an ongoing Risk Factors study, described previously [25] . NIDUs were defined as persons who used heroin and/or cocaine in the prior 6 months but who had never injected an illicit drug. Briefly, research staff examined the intake records in the admission wards of the detoxification program to identify patients admitted within the past 3 days. Patients that were eligible and willing to participate were enrolled in the study and paid an honorarium of $20. To minimize the likelihood of misclassification, we enrolled both persons who had injected and those who had used but not injected illicit drugs. Subjects who consented to participation in this substudy received an additional $10. All subjects were interviewed by trained personnel using a structured questionnaire that covers demographics, sexual risk behaviours, and detailed questions on both injecting and noninjecting drug use. Fifteen healthy individuals without risk factors for HCV infection and who had never used drugs, other than marijuana smoked as a cigarette, were included as negative controls. All study participants provided a 60 mL blood sample.
The study protocol was approved by the Weill Cornell Medical College (WCMC) and BIMC Institutional Review 
Samples
Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) plasma tubes and transported to WCMC for the same day processing. PBMCs were isolated using FicollHypaque density gradient centrifugation within 2-6 h of specimen collection and immediately used in an interferongamma (IFN-c) enzyme-linked immunospot (ELISpot) assay. Plasma was cryopreserved for future testing.
Hepatitis C virus antibody and RNA testing
Hepatitis C virus antibody and RNA testing was performed using frozen plasma samples. HCV antibodies were assayed using Ortho Vitros Eci anti-HCV antibody test (Ortho-Clinical Diagnostics, Raritan, NJ, USA). The presence of HCV RNA was determined using Roche Diagnostics Cobas Taqman Real-Time PCR test with the lower detection limit of 43 IU/ mL (Roche Diagnostics, Indianapolis, IA, USA).
Enzyme-linked immunospot assay
Enzyme-linked immunospot assay was performed as previously described [23] . Briefly, 428 peptides encompassing the complete HCV genotype 1a polyprotein were pooled in 21 mixtures and used as antigens. PBMCs were plated on 96-well plates (300 000 cells/well) and stimulated in triplicate with each peptide mix and the following positive controls: phorbol mystriate acetate (Sigma Chemicals, St Louis, MO, USA), tetanus toxoid (Accurate Chemicals & Scientific Corporation, Westbury, NY, USA) and Candida albicans cellular antigen (Greer, Lenoir, NC, USA). Each plate had at least 6 no-antigen control wells, and each plate with more than 10 spot-forming cells (SFC) per no-antigen control well, on average, was eliminated from the study. Responses were considered positive if, after subtraction of the background, the mean number of SFC was ‡10 and at least greater than the mean +2 standard deviations of the SFC from healthy controls for the respective peptide mix. Patients were considered positive for HCV-specific cellular responses if more than one peptide mix was positive according to the above criteria.
Statistical analysis
We used t test for equality of means to assess group difference among continuous variables. We used the PearsonÕs chi square test for assessing the independence of predictor and outcome variables when the predictors were categorical. We also conducted logistic regression analysis for maximumlikelihood estimation and to obtain odds ratios. All tests were Ó 2012 Blackwell Publishing Ltd conducted in Stata, version 11 (College Station, TX, USA). Statistical tests were considered significant when probability of type I error was <5% (P < 0.05).
RESULTS
Study subjects
Fifty-seven NIDUs and 15 healthy controls, with average ages of 44 and 45 years, respectively, were enrolled in this study ( Table 1 ). The vast majority of NIDUs were Black (63%) or Hispanic (32%) as compared to the controls, 73% of whom were White. Sixty-eight percent of NIDUs had smoked crack compared with 37% whom had sniffed or snorted cocaine. Similar results were observed among those with HCV-specific antibody or cellular responses. Among those with positive serological responses, 73% indicated that they had smoked crack and 37% had sniffed or snorted cocaine. Similar trends were observed for patients who had detectable HCV-specific cellular responses.
Hepatitis C virus prevalence
Hepatitis C virus antibodies were detected in 11 out of 57 NIDUs (19.3%). Seven of these individuals had HCV infection, as indicated by HCV RNA positivity. The remaining four seropositive NIDUs had spontaneously resolved HCV infection in the past, as there was no detectable HCV RNA in their blood.
The ELISpot assay was performed in 51 NIDUs, and we found HCV-specific cellular immune responses in 5 (9.8%). These responses were relatively weak and narrow.
Associations between demographic and behavioural factors and HCV-specific immune responses
We analyzed potential differences in demographic and behavioural characteristics between NIDUs with HCV-specific antibody or cellular immunity and those that were negative on both Ab and ELISpot tests. We also compared seropositive NIDUs with those that were seronegative and those that were negative on both tests and NIDUs with positive HCV-specific cellular immunity with those that had negative ELISpot or were negative on both ELISpot and Ab tests. The results of these comparisons are presented in Table 2 . We did not find any associations between HCVspecific immune responses and recent noninjection drug use practices. However, subjects who were positive on either HCV Ab or ELISpot tests were more likely to report having more casual opposite sex partners in the last 6 months (P = 0.02), to report having casual sex partners of the opposite gender who had ever injected drugs (P = 0.03), to be male who had ever had sex with a male partner (P = 0.05), or to have bought sex (P = 0.03) in the past 6 months compared to subjects who did not have serologic or cellular responses. Similarly, when we compared seropositive subjects with those who are seronegative, seropositive NIDUs had significantly more casual opposite sex partners in the last 6 months (P = 0.02). NIDUs with a positive ELISpot reported significantly more casual opposite sex partners that have ever injected drugs compared with NIDUs with negative ELISpot (P = 0.01). We did not find any demographic differences between subjects with or without HCV-specific immune responses. The modest number of subjects, the multiple outcome measures (anti-HCV, ELISpot) and the inter-correlations among the sexual behaviour variables precluded meaningful multivariate analyses.
DISCUSSION
In this study, 19.3% of analyzed NIDUs were found to be HCV seropositive, while 9.8% had detectable, although weak HCV-specific cellular immune responses. Overall, 27.5% of study participants had either HCV-specific antibodies or cellular immunity, which is considerably higher compared to the general population in which HCV prevalence is estimated to be 1.7% [3] . Our findings are well within the 2-35% HCV seroprevalence range previously reported among NIDUs [11] . Surprisingly, we did not find any associations between patterns of noninjecting drug use behaviours and HCVspecific immune responses. However, we identified multiple associations between HCV-specific immunity and sexual behaviours, including having more casual opposite sex partners, having sex partners who had ever injected drugs, buying sex, and ever having male-to-male sex. We believe our findings do not necessarily indicate that HCV exposure occurred only though sexual activities among our subjects. Our measures of both sexual and noninjecting drug use behaviours covered only 6 months prior to the interview, and most HCV exposures probably occurred years earlier. Additionally, having an IDU sexual partner suggests a very high likelihood of contact with an HCV-infected individual. NIDUs with IDU sexual partners may engage in noninjecting drug use and sexual activities simultaneously, Table 2 NIDUs, noninjection drug users; HCV, hepatitis C virus; Ab, antibody; ELISpot, enzyme-linked immunospot assay; OD, odds ratio; CI, confidence interval; Avg, average; SD, standard deviation.
Ó 2012 Blackwell Publishing Ltd which is particularly common when stimulants, such as crack cocaine, are taken [26] . In such a case, it would be difficult to ascertain which of the two behaviours transmitted HCV. The use of stimulant drugs may also prolong sexual intercourse [27] , while their vasoconstricting effects may decrease recto-vaginal secretion, consequently enhancing the possibility of tissue abrasions that can lead to blood-toblood contact and HCV transmission. In this study, none of the subjects had both HCV-specific antibody and cellular immunity. Of 11 seropositive individuals, 7 had chronic HCV infection while 4 had spontaneously cleared the infection. In general, individuals who do not eradicate HCV have weak or undetectable HCV-specific T-cell responses, which is partially the reason for HCV persistence [28] . Consequently, our finding of negative ELISpot results in patients with chronic HCV infection is not surprising. Additionally, our previous work showed that almost half of IDUs who spontaneously cleared HCV do not have detectable T-cell responses [23] . Therefore, as we were unable to perform the ELISpot in two of our NIDU subjects with spontaneous HCV resolution, a lack of overlap between detectable cellular and serologic HCV-specific immune responses in our study population is not unexpected.
Limitations of this work include the relatively modest number of subjects, which may have impacted on our ability to detect significant associations between noninjection drug use patterns and HCV-specific immunity. Our questions covered the preceding 6 months, while HCV exposure probably happened much earlier. Consequently, meaningful associations would occur only if recent behaviours represented long-standing patterns. Lack of questions regarding tattoos, body piercings or blood transfusions, all associated with HCV acquisition, is another limitation of the study. Finally, our behavioural data were based on self-reports, and thus are subject to possible social desirability bias. In particular, some subjects might have injected drugs, but denied doing so during the interviews. However, we did find multiple relationships between HCV immunity and socially undesirable behaviours, e.g. reporting paying for sex, which suggests that social desirability did not completely obscure relationships between behaviour and HCV exposure.
In summary, we found HCV prevalence to be much higher in this cohort of NIDUs compared to that in the general population. HCV seroprevalence was not associated with recent noninjection drug use practices and was associated with recent sexual behaviours. However, given the likely overlap between sexual and drug use partners, we believe that both noninjection drug use and sexual behaviours should be considered potential routes of HCV transmission. We would note the great difficulties in trying to separate sharing of noninjecting drug use equipment from sexual intercourse as routes of HCV transmission among NIDUs. Even though HCV prevalence is clearly elevated among NIDUs, exposure to HCV is still a relatively rare event. Thus, large number of patients would need to be followed for long periods of time in order to identify specific drug use and sexual behaviours associated with HCV exposure among NIDUs. Until additional studies are conducted, we would suggest warning NIDUs that HCV might be transmitted through both sharing of drug equipment and through sexual activity.
